AU2007203079B2 - N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4- [1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide as an anticancer agent - Google Patents

Description

A ustralian Patents Act 1990 - Regulation 3.2 ORIGINAL COMPLETE SPECIFICATION STANDARD PATENT Invention Title "N-(3-nethoxy-5-methylpyrazin-2-yl)-2-(4-[I,3,4-oxadiazol-2-yl Iphenyl)pyridine-3 sulphonamide as an anticancer agent" The following statement is a full description of this invention, including the best method of performing it known to me/us: P1/00/011 P \OPER\DAf3(255 I dv spc doc -2 ?2m? N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-11,3,4-oxadiazol-2-yll phenyl)pyridine-3 sulphonamide as an anticancer agent This is a divisional of Australian Patent No. 2003255835, the entire contents of which are incorporated herein by reference. 5 The present application refers to N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4 oxadiazol-2-yljphenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, hereafter "Compound (I)", and its use in the treatment of cancer in a warm blooded animal such as man. The invention also relates to the use of pharmaceutical compositions containing Compound (I), or a pharmaceutically acceptable salt thereof, in a method of treating cancer in a warm blooded animal such as man, and to the use of Compound (1), or a 10 pharmaceutically acceptable salt thereof, in the manufacture of medicament for use in a method of treating cancer in a warm blooded animal such as man. The invention also relates to-the use of pharmaceutical compositions containing Compound (I), or a pharmaceutically acceptable salt thereof, in a method of treating pain in a warm blooded animal such as man, and-to the use of Compound (I), or a pharmaceutically acceptable salt thereof, in the 15 manufacture of medicament for use treating pain in a warm blooded animal such as man. Cancer affects an estimated 10 million people worldwide. This figure includes incidence, prevalence and mortality. More than 4.4 million cancer cases are reported from Asia, including 2.5 million cases from Eastern Asia, which has the highest rate of incidence in the world. By comparison, Europe has 2.8 million cases, North America 1.4 million cases, and Africa 627,000 cases. 20 In the UK and US, for example, more than one in three people will develop cancer at some point in their life. Cancer mortality in the U.S. is estimated to account for about 600,000 a year, about one in every four deaths, second only to heart disease in percent of all deaths, and second to accidents as a cause of death of children 1-14 years of age. The estimated cancer incidence in the U.S. is now about 1,380,000 new cases annually, exclusive of about 900,000 cases of non-melanotic (basal and squamous cell) skin cancer. 25 Cancer is also a major cause of morbidity in the UK with nearly 260,000 new cases (excluding non-melanoma skin cancer) registered in 1997. Cancer is a disease that affects mainly older people, with 65% of cases occurring in those over 65. Since the average life expectancy in the UK has almost doubled since the mid nineteenth century, the population at risk of cancer has grown. Death rates from other causes of death, such as heart disease, have fallen in recent years while deaths from cancer have remained relatively stable. The result is 30 that I in 3 people will be diagnosed with cancer during their lifetime and I in 4 people will die from cancer. In people under the age of 75, deaths from cancer outnumber deaths from 2 diseases of the circulatory system, including ischaermic heart disease and stroke. In 2000, there were 151,200 deaths from cancer. Over one fifth (22 per cent) of these were from lung cancer, and a quarter (26 per cent) from cancers of the large bowel, breast and prostate. Worldwide, the incidence and mortality rates of certain types of cancer (of stomach, 5 breast, prostate, skin, and so on) have wide geographical differences which are attributed to racial, cultural, and especially environmental influences. There are over 200 different types of cancer but the four major types, lung, breast, prostate and colorectal, account for over half of all cases diagnosed in the UK and US. Prostate cancer is the fourth most common malignancy among men worldwide, with an estimated 400,000 new cases diagnosed annually, accounting 10 for 3.9 percent of all new cancer cases. Current options for treating cancers include surgical resection, external beam radiation therapy and / or systemic chemotherapy. These are partially successful in some forms of cancer, but are not successful in others. There is a clear need for new therapeutic treatments. Non-steroidal anti-inflammatory drugs (NSAIDS) and opiates are the main classes of 15 drugs in pain relief. However both possess undesirable side effects. NSAIDS are known-to cause gastrointestinal irritation and opiates are known to be addictive. There is thus also a clear need for new treatments for the management and treatment of pain. Recently, endothelin A receptor antagonists have been identified as potentially of value in the treatment of cancer (Cancer Research, 56, 663-668, February 15w', 1996 and 20 Nature Medicine, Volume 1, Number 9, September 1999, 944-949). The endothelins are a family of endogenous 21 amino acid peptides comprising three isoforms, endothelin-1 (ET-1), endothelin-2 and endothelin-3. The endothelins are formed by cleavage of the Trp 21 -Val2 bond of their corresponding proendothelins by an endothelin converting enzyme. The endothelins are among the most potent vasoconstrictors known and 25 have a characteristic long duration of action. They exhibit a wide range of other activities including cell proliferation and mitogenesis, extravasation and chemotaxis, and also interact with a number of other vasoactive agents. The endothelins are released from a range of tissue and cell sources including vascular endothelium, vascular smooth muscle, kidney, liver, uterus, airways, intestine and leukocytes. 30 Release can be stimulated by hypoxia, shear stress, physical injury and a wide range of hormones and cytokines. Elevated endothelin levels have been found in a number of disease states in man including cancers.

3 The present invention concerns the surprising finding that Compound (I) is a particularly potent anti-cancer agent. Compound (1) is described as an endothelin receptor antagonist in W096/40681, and although in W096/40681 it is acknowledged that elevated endothelin levels have been found in a number of disease states in man including certain 5 cancers, there is no hint or suggestion that this compound would possess the particular beneficial efficacious, metabolic and toxicological profiles that makes it such a potent anti cancer agent. W096/40681 claims the endothelin receptors described therein solely for cardiovascular diseases. For example in the introduction it is stated these compounds are useful in the treatment of diseases or medical conditions including "hypertension, pulmonary 10 hypertension, cardiac or cerebral circulatory disease and renal disease". The claims list the following medical disease states "hypertension, pulmonary hypertension, congestive heart failure, dyslipidaemia, atherosclerosis, restenosis, acute and chronic renal failure, ischaemic stroke, subarachnoid haemorrhage, intermittent claudication, critical limb ischaemia, asthma or organ failure after general surgery or transplantation". There is no hint or suggestion from 15 W096/40681 that this compound would possess the particular beneficial efficacious, metabolic and toxicological profiles that makes it such a potent anti-cancer agent. In fact, the present inventors have surprisingly established that Compound (I) is a specific endothelin-A (ETA) antagonist and has no measurable activity against endothelin-B (ETn). The ETA receptor has been shown, via a variety of mechanisms, to be the more 20 important pathological receptor of the two identified endothelin receptors in oncology: in the reduction of abnormal cell proliferation (Bagnato et. al., (1995), Clin Cancer Res 1, 1059 1066); as a anti-apoptotic (Wu Wang et. al., (1997), Biochem J,. 328, 733-737); as an anti angiogenic agent (Spinella et al., (2002), J. Biol. Chem, 227(31), 27850-27855); and as an inhibitor of bone metastases (Guise et. al., ASCO (2000) abstract 331 and Nelson, et. al., Z5 (1999), Urology 53, 1063-1069) in addition to mediating pain which is a common co morbidity in cancer. It has been shown (Dahlof et al., (1990), J Hypertens, 8, 811- 817) that large doses of endothelin-l causes pain, and causes pain sensitization, but that this can be inhibited by an ETA antagonist (e.g. Davar et al., (1998), Neuroreport 9, 2279-2283 and De Mello et al., (1998), Pain, 77, 261-269). Therefore in another aspect of the invention, 10 Compound (I) is administered for the prevention or treatment of pain mediated by the endothelin system, in particular that associated with elevated endothelin- I levels. Conversely, there is emerging evidence (e.g. Cattaruzza et. al., (2002), FASEB J. 14(7), 991-998 and Okazawa et. al., (1998), J Biol Chem, 273, 12581-12592) that the ETa 4 receptor is involved in apoptotic signalling. The blocking of pro-apoptotic pathways would be undesirable in the treatment of cancer, hence a compound that specifically targeted the ETA receptor while leaving the ETB receptor unaffected would be of the greatest utility in the treatment of cancer. Compound (I) is such a compound. 5 Compound (I) by acting specifically on the ETA receptor has many advantages over endothelin antagonists that also have measurable ETs activity. For instance Compound (1) could be administered to a patient without the administrator or prescribing medical practitioner needing to titrate the dose of Compound (I) looking for signs of ETB activity (for example oedema). Furthermore, larger doses could potentially be administered because there 10 would be no ETB side effects. Another disadvantage of ETa inhibition is that it causes a rise in plasma endothelin. Potentially, over the course of treatment, for a mixed ETA / ETE inhibitor, or a compound that selectively targeted the ETA receptor, but still had measurable ETB activity, this would result in increasingly larger doses of inhibitor being needed to have the same beneficial ETA effects. 15 A specific ETA inhibitor would not encounter this problem. Therefore according to the present invention, there is provided Compound (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer in a warm blooded animal such as man. In one aspect, where Compound (I), or a pharmaceutically acceptable salt thereof, is 20 referred to this refers to the compound only. In another aspect this refers to a pharmaceutically acceptable salt of Compound (I). According to another feature of the present invention, there is provided Compound (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of cancer in a warm blooded animal such as man. 25 According to a further feature of this aspect of the invention there is provided a method of treating cancer which comprises administering an effective amount of Compound (I), or a pharmaceutically acceptable salt thereof, to a warm blooded animal such as man. According to a further feature of this aspect of the invention there is provided a pharmaceutical composition which comprises Compound (I), or a pharmaceutically 30 acceptable salt thereof, in association with a pharmaceutically acceptable diluent or carrier for use in the treatment of cancer in a warm blooded animal such as man. In another aspect of the invention there is provided the use of Compound (I), or a pharmaceutically acceptable salt thereof, in the reduction of abnormal proliferation in a 5 cancerous cell or inducing differentiation of a cancerous cell in a warm blooded animal such as man. In another aspect of the invention there is provided the use of Compound (1), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the 5 reduction of abnormal proliferation in a cancerous cell or inducing differentiation of a cancerous cell in a warm blooded animal such as man. In another aspect of the invention there is provided a method for reducing abnormal proliferation in a cancerous cell or inducing differentiation of a cancerous cell which comprises administering an effective amount of Compound (I), or a pharmaceutically 10 acceptable salt thereof, to a warm blooded animal such as man. According to a further feature of this aspect of the invention there is provided a pharmaceutical composition which comprises Compound (I), or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable diluent or carrier for use in the reduction of abnormal proliferation in a cancerous cell or inducing differentiation of 15 a cancerous cell in a warm blooded animal such as man. In another aspect of the invention there is provided the use of Compound (I), or a pharmaceutically acceptable salt thereof, in inducing apoptosis in a cancerous cell in a warm blooded animal such as man. In another aspect of the invention there is provided the use of Compound (1), or a 20 pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in inducing apoptosis in a cancerous cell in a warm blooded animal such as man. In another aspect of the invention there is provided a method of inducing apoptosis in a cancerous cell which comprises administering an effective amount of Compound (I), or a pharmaceutically acceptable salt thereof, to a warm blooded animal such as man. 25 According to a further feature of this aspect of the invention there is provided a pharmaceutical composition which comprises Compound (), or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable diluent or carrier for use in inducing apoptosis in a cancerous cell in a warm blooded animal such as man. In another aspect of the invention there is provided the use of Compound (I), or a 30 pharmaceutically acceptable salt thereof, as an anti-angiogenic and vascular targeting agent in blood vessels supplying a cancerous cell in a warm blooded animal such as man. In another aspect of the invention there is provided the use of Compound (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use as an 6 anti-angiogenic and vascular targeting agent in blood vessels supplying a cancerous cell in a warm blooded animal such as man. In another aspect of the invention there is provided a method of providing an anti angiogenic and vascular targeting agent in blood vessels supplying a cancerous cell which 5 comprises administering an effective amount of Compound (1), or a pharmaceutically acceptable salt thereof, to a warm blooded animal such as man. According to a further feature of this aspect of the invention there is provided a pharmaceutical composition which comprises Compound (I), or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable diluent or carrier for 10 use as an anti-angiogenic and vascular targeting agent in blood vessels supplying a cancerous cell in a warm blooded animal such as man. By the term "vascular targeting agent" it is to be understood that the site of action of Compound (1) would be on the vasculature itself rather than the tumour. In another aspect of the invention there is provided the use of Compound (I), or a 25 pharmaceutically acceptable salt thereof, as an anti-angiogenic agent in a warm blooded animal such as man. In another aspect of the invention there is provided the use of Compound (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use as an anti-angiogenic agent in a warm blooded animal such as man. 20 In another aspect of the invention there is provided a method of providing an anti angiogenic effect which comprises administering an effective amount of Compound (I), or a pharmaceutically acceptable salt thereof, to a warm blooded animal such as man. According to a further feature of this aspect of the invention there is provided a pharmaceutical composition which comprises Compound (1), or a pharmaceutically 25 acceptable salt thereof, in association with a pharmaceutically acceptable diluent or carrier for use as an anti-angiogenic agent in a warm blooded animal such as man. In another aspect of the invention there is provided the use of Compound (I), or a pharmaceutically acceptable salt thereof, as an inhibitor of bone metastases and an inhibitor of invasion in a warm blooded animal such as man. 30 In another aspect of the invention there is provided the use of Compound (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use as an inhibitor of bone metastases and an inhibitor of invasion in a warm blooded animal such as man.

7 In another aspect of the invention there is provided a method of inhibiting bone metastases and inhibiting invasion which comprises administering an effective amount of Compound (I), or a pharmaceutically acceptable salt thereof, to a warm blooded animal such as man. 5 According to a further feature of this aspect of the invention there is provided a pharmaceutical composition which comprises Compound (I), or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable diluent or carrier for use as an inhibitor of bone metastases and an inhibitor of invasion in a warm blooded animal such as man. 10 In another aspect of the invention there is provided the use of Compound (I), or a pharmaceutically acceptable salt thereof, as an inhibitor of bone metastases in a warm blooded animal such as man. In another aspect of the invention there is provided the use of Compound (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use as an 15 inhibitor of bone metastases in a warm blooded animal such as man. In another aspect of the invention there is provided a method of inhibiting bone metastases which comprises administering an effective amount of Compound (I), or a pharmaceutically acceptable salt thereof, to a warm blooded animal such as man. According to a further feature of this aspect of the invention there is provided a 20 pharmaceutical composition which comprises Compound (I), or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable diluent or carrier for use as an inhibitor of bone metastases in a warm blooded animal such as man. In another aspect of the invention there is provided the use of Compound (I), or a pharmaceutically acceptable salt thereof, in the prevention of bone metastases in a warm 25 blooded animal such as man. In another aspect of the invention there is provided the use of Compound (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the prevention of bone metastases in a warm blooded animal such as man. In another aspect of the invention there is provided a method of preventing bone 30 metastases which comprises administering an effective amount of Compound (I), or a pharmaceutically acceptable salt thereof, to a warm blooded animal such as man. According to a further feature of this aspect of the invention there is provided a pharmaceutical composition which comprises Compound (I), or a pharmaceutically 8 acceptable salt thereof, in association with a pharmaceutically acceptable diluent or carrier for use in the prevention of bone metastases in a warm blooded animal such as man. In another aspect of the invention there is provided the use of Compound (I), or a pharmaceutically acceptable salt thereof, in the treatment of bone metastases in a warm 5 blooded animal such as man. In another aspect of the invention there is provided the use of Compound (1), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of bone metastases in a warm blooded animal such as man. In another aspect of the invention there is provided a method of treating bone 10 metastases which comprises administering an effective amount of Compound (I), or a pharmaceutically acceptable salt thereof, to a warm blooded animal such as man. According to a further feature of this aspect of the invention there is provided a pharmaceutical composition which comprises Compound (I), or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable diluent or carrier for 15 use in the treatment of bone metastases in a warm blooded animal such as man. In a further aspect of the invention, there is provided the inhibition, treatment and / or prevention of bone metastases, as described herein, wherein the bone metastases are as a result of renal, thyroid, lung, breast or prostate cancer. In another aspect of the invention there is provided the use of Compound (I), or a 20 pharmaceutically acceptable salt thereof, in the prevention or treatment of pain associated with elevated endothelin- I production in a warm blooded animal such as man. In another aspect of the invention there is provided the use of Compound (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the prevention or treatment of pain associated with elevated endothelin-1 production in a warm 25 blooded animal such as man. In another aspect of the invention there is provided a method of treating pain associated with elevated endothelin-1 production which comprises administering an effective amount of Compound (1), or a pharmaceutically acceptable salt thereof, to a warm blooded animal such as man. 30 According to a further feature of this aspect of the invention there is provided a pharmaceutical composition which comprises Compound (I), or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable diluent or carrier for C:WRPonbl\DCC\KZL\2586272_L.DOC-19/1/2009 -9 use in the prevention or treatment of pain associated with elevated endothelin- 1 production in a warm blooded animal such as man. In another aspect of the invention there is provided the use of Compound (I), or a pharmaceutically acceptable salt thereof, in the prevention or treatment of pain in a warm 5 blooded animal such as man. In another aspect of the invention there is provided the use of Compound (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the prevention or treatment of pain in a warm blooded animal such as man. In another aspect of the invention there is provided a method of treating pain which 10 comprises administering an effective amount of Compound (I), or a pharmaceutically acceptable salt thereof, to a warm blooded animal such as man. In another aspect of the invention there is provided a method of treating or preventing pain comprising administering to a warm blooded animal in need thereof Compound (I), or a pharmaceutically acceptable salt thereof. 15 In another aspect of the invention there is provided the use of Compound (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the prevention or treatment of pain associated with elevated endothelin-1 production in a warm blooded animal. In another aspect of the invention there is provided a method of treating or preventing 20 pain associated with stimulation of the ETA receptor comprising administering to a warm blooded animal in need thereof Compound (I), or a pharmaceutically acceptable salt thereof. In another aspect of the invention there is provided a method of treating or preventing pain associated with elevated endothelin-I production comprising administering to a warm blooded animal in need thereof Compound (I); or a pharmaceutically acceptable salt thereof. 25 In another aspect of the invention there is provided the use of Compound (I), or a pharmaceutically acceptable salt thereof in the prevention or treatment of pain associated with stimulation of the ETA receptor in a warm blooded animal such as man. In another aspect of the invention there is provided the use of Compound (1), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the 30 prevention or treatment of pain associated with stimulation of the ETA receptor in a warm blooded animal such as man. In another aspect of the invention there is provided a method of treating pain associated with stimulation of the ETA receptor which comprises administering an effective amount of Compound (I), or a pharmaceutically acceptable salt thereof, to a warm blooded animal such C \NPonblDCC\KZL\286272I..DOC-19/1112009 - 9A as man. Where cancer is referred to, particularly it refers to oesophageal cancer, myeloma, hepatocellular, pancreatic, cervical cancer, ewings tumour, neuroblastoma, Kaposis sarcoma, ovarian cancer, breast cancer, colorectal cancer, prostate cancer, bladder cancer, melanoma, 5 lung cancer - non small cell lung cancer (NSCLC), and small cell lung cancer (SCLC) gastric cancer, head and neck cancer, renal cancer, lymphoma and leukaemia. More particularly it refers to prostate cancer. In addition, more particularly it refers to SCLC, NSCLC, colorectal cancer, ovarian cancer and/or breast cancer. In addition, more particularly it refers to SCLC. In addition, more particularly it refers to NSCLC. In addition, 10 more particularly it refers to colorectal cancer. In addition, more particularly it refers to ovarian cancer. In addition, more particularly it refers to breast cancer. Furthermore, more particularly it refers to bladder cancer, oesophageal cancer, gastric cancer, melanoma, cervical 10 cancer and / or renal cancer. In addition it refers to endometrial, liver, stomach, thyroid, rectal and / or brain cancer. In another aspect of the invention, the cancer is not melanoma. In another embodiment of the invention, particularly the cancer is in a metastatic state, and more particularly the cancer produces metastases to the bone. In a further embodiment of the 5 invention, particularly the cancer is in a metastatic state, and more particularly the cancer produces skin metastases. In a further embodiment of the invention, particularly the cancer is in a metastatic state, and more particularly the cancer produces lymphatic metastases. In a further embodiment of the invention, the cancer is in a non-metastatic state. It is to be understood that when the cancer is in a metastatic state, that Compound (I) 10 acts at both the primary tumour site and the metastases. Compound (1) both prevents, treats and inhibits metastases. In one aspect of the invention, where pain is referred to, this is pain associated with raised endothelin-I levels. In another aspect of the invention this is pain associated with stimulation of the ETA receptor resulting from situations where ETB down-regulation has 15 occurred leading to abnormal ETA stimulation and/or elevation of endothelin-I levels. Particularly this is pain associated with cancer. More particularly it is pain associated with prostate cancer. According to a further feature of this aspect of the invention there is provided a pharmaceutical composition which comprises Compound (I), or a pharmaceutically 20 acceptable salt thereof, in association with a pharmaceutically acceptable diluent or carrier for use in the prevention or treatment of pain associated with stimulation of the ETA receptor in a warm blooded animal such as man. Additionally, Compound (I) is expected to be useful in the treatment and/or prophylaxis of pain of different origins and causes, including acute as well as chronic pain 25 states. Examples are pain caused by chemical, mechanical, radiation (including sunburn), thermal (including burns), infectious or inflammatory tissue trauma or cancer, postoperative pain, post-partum pain, the pain associated with joint conditions (such as rheumatoid arthritis and osteoarthritis), pain associated with dental conditions (such as dental caries and gingivitis), myofascial and low back pain, pain associated with bone disorders (such as 30 osteoporosis, hypercalcaemia of malignancy and Paget's disease) and the pain associated with sports injuries and sprains. Also neuropathic pain conditions of central or peripheral origin could be treated or prevented with Compound (I). Examples of these pain conditions are pain associated with 11 trigeminal neuralgia, pain associated with postherpetic neuralgia (PHN), pain associated with diabetic mono/poly neuropathy, pain associated with nerve trauma, pain associated with spinal cord injury, pain associated with central post stroke, pain associated with multiple sclerosis and pain associated with Parkinson's disease. 5 Other pain states of visceral origin such as caused by ulcer, dysmenorrhea, endometriosis, irritable bowel syndrome, dyspepsia, pelvic pain etc. could also be treated or prevented with Compound (I). Additionally, Compound (1) is expected to be useful in the treatment and/or prophylaxis of additional types of pain for example complex regional pain syndrome, 10 vasospastic/ischemic pains (e.g. Raynaud syndrome) and bone pain. A further aspect of the invention is to use Compound (I) for oral treatment of neuropathic or central pain states. Suitable pharmaceutically-acceptable salts include, for example, salts with alkali metal (such as sodium, potassium or lithium), alkaline earth metals (such as calcium or magnesium), 15 ammonium salts, and salts with organic bases affording physiologically acceptable cations, such as salts with methylamine, dimethylamine, trimethylamine, piperidine and morpholine. In addition, suitable pharmaceutically-acceptable salts include, pharmaceutically-acceptable acid-addition salts with hydrogen halides, sulphuric acid, phosphoric acid and with organic acids such as citric acid, maleic acid, methanesulphonic acid and p-toluenesulphonic acid. 20 Legends to Figures Figure 1: This is a Western Blot showing inhibition of ET-1 induced MAPK phosphorylation with Compound (I) in the osteoblast cell line MC3T3.El/J1 from study 2 below. The proteins have been run on a gel then transferred over to a nitrocellulose membrane, where they are probed for using the primary and secondary antibodies. The 25 following abbreviations are used: SCM: serum containing media SFM: serum free media Figure 2: This is a graph depicting, inhibition of ET-1 induced MAPK phosphorylation with Compound (I) in the osteoblast cell line MC3T3.El/JI also from study 2. 30 The following in vivo and in vitro studies can be used to determine the efficacy of Compound (1) in oncology.

12 1) Endothelin human receptor binding assay Human recombinant ETA or ETB receptors were expressed in mouse erythroleukasmic (MEL) cells and membranes prepared for competition binding studies using m1-labelled ET- I as the radioligand. Incubations were carried out in triplicate in the presence of Compound (I), 5 10-11 - 104 M in half log increments, and inhibition of ET-1 binding was expressed as a geometric mean plCso value with 95% confidence limits. Results The plCso (negative log of the concentration of compound required to displace 50% of the ligand) for Compound (I) at the ETA receptor was 8.27 (8.23 - 8.32) (n=4). Displacement 10 curves were normal with slopes close to unity. Compound (I) had no measurable affinity for the ETB receptor with a mean displacement of 1.2 + 0.7% (n=3) at a concentration of 10 4 M, a figure well within the limits of sensitivity of the assay. Conclusion Compound (I) is a high affinity ligand for the human ETA receptor and is ETA 15 specific, having no significant ETD receptor affinity. 2) Compound (1) as a treatment for Metastatic Cancer: Osteoblast data - Inhibition of ET-1 induced MAPK stimulation with Compound (I) Compound (I) may well have a role in the treatment of not only primary tumours but also metastatic tumours and the pathological production of new bone in and around metastatic 20 deposits. Described below is an experiment demonstrating the utility of Compound (1) in treating the osteoblastic bone pathology. The important clinical pathology seen in the bone metastatic regions of patients with advanced prostate cancer presents as an inappropriate osteoblastic stimulation, i.e. the presence of prostatic tumour metastases in bone results in the net production of new bone and 25 eventually an increase in bone density around the metastatic deposit (reviewed in Cancer Metastasis Rev. 2001; 20(3-4):333-49). The hypothesised mechanism behind this pathology is a release of ET- 1 from the metastatic prostate cell in the early establishment of the secondary bone tumour. ET- I stimulation of the osteoblast has been described as the key step in the 30 pathological formation of new bone in prostate bone metastasis (Invest New Drugs. 2002; 20(2):173-82). It has been shown that ET-1 acts to directly induce proliferation and differentiation of the osteoblast, as well as stimulate the osteoblast to produce other growth factors, by simulation of the ETA receptor and subsequent phosphorylation of MAP kinase 13 (Bone. 1999; 24(4):315-20 and J Bone Miner Res. 2002; 17(10):1774-84). In this way stimulation of the ETA receptor causes both growth of bone and also, by release of growth factors into the local environment, survival and growth of the metastatic tumour cell. The tumour cells and osteoblastic cells in a metastatic deposit therefore participate in a "vicious 5 cycle" in which their proliferative responses support each other, overcoming the normal regulatory mechanisms which control and limit bone formation (Nat Rev Cancer. 2002; 2(8): 584-93). In the experiments described below the present inventors first demonstrate the ability of ET-1 to stimulate MAP kinase in osteoblastic cells. This stimulation promotes proliferation 10 of the cells and activation of the pathways shown to be important in the release of growth factors from the osteoblast. The inventors then demonstrate that Compound (I), an ETA antagonist is an effective antagonist of this ET-1 stimulation. Method 15 The MC3T3. E1/J1 cell line was isolated from a parental cell line, MC3T3-El (available from Invitrogen), which had in turn been derived from newborn C57BL/6 mouse calvaria. The MC3T3 E1/JI line is described as an osteoblastic line. To initiate the experiments described below, MC3T3.E1/J1 cells were plated at a density of 2.4x104 cells/well (24 well plates) in serum containing media and incubated for 48 hours. The cells 20 were washed twice in PBS and re-incubated for approximately 17 hours in serum starvation media. At this stage, cells were then incubated with or without Compound (1) for 30 minutes then stimulated with growth factor (PDGF or ET-1) for 3 minutes. All media was then removed and the cells lysed and stored at -20*C for electrophoresis/westem blot, which 25 localized phosphorylated MAPK and phosphorylated Akt probing with anti-phospho-p44/42 MAPK (Thr 202/204) and anti-Phospho AKT (Ser 473) antibodies (both commercially available from Cell Signalling Technology). The protein bands were quantitated by densitometry, and plotted as arbitrary densitometry units. Phosphorylated MAPK levels were normalised to total MAPK levels. 30 Results Stimulation of cells with ET- I for 3 minutes resulted in increased phosphorylation of MAPK in the osteoblast cell line MC3T3.E1/JI. Stimulation of the cells with a standard 14 growth factor, PDGF, also resulted in increased phosphorylation of MAPK. Compound (I) inhibited ET-1-induced MAPK phosphorylation in osteoblasts. Table 1 Inhibition of ET-1 induced MAPK phosphorylation with Compound (1) in the osteoblast cell line MC3T3.E1/Jl Environment Average Complete Media 151.70 Serum Free Media 100.00 ET- 100nin 312.78 ET-1 100nm 369.85 + Compound (I) 20 pm 109.18 + Compound (I) 10 prm 105.15 + Compound (I) 1pm 157.41 + Compound (1) 0.1 pm 22.11 5 Table I This data is represented in Figures 1 and 2. Note: The above experiment is not reliant on use of the particular MC3T3.E1/J1 cell line, it could, for example, be performed using the commercially available parental cell line MC3T3-E1. 10 3) Compound (I) as an inhibitor of angiogenesis ETA receptor activation by ET-1 contributes to tumour growth and progression, mediated by various mechanisms in the literature to suggest that specifically inhibiting ETA will produce beneficial effects on primary tumours quite separate to its effects on bone metastases. These mechanisms include anti-apoptosis, direct and indirect growth promotion 15 and promotion of cell motility (Nat Rev Cancer. 2003; 3(2): 110-6). Of more recent and increasing interest is the role of ET-1 mediated by the ETA receptor as key players in tumour angiogenesis (J Cardiovasc Pharmacol. 2000; 36: S 135-9). Mechanistic studies have now shown that the ETA receptor is important in the production of the potent angiogenic factor VEGF (Life Sci. 1998; 63(6): 477-84) by direct induction of a 20 hypoxia-inducible factor, HIF-1 a (J Biol Chem. 2002; 277: 27850-5). The increasing literature to support the role of endothelin and the ETA receptor in tumour angiogenesis was reviewed very recently by Bagnato and Spinella, (Trends Endocrinol Metab. 2003; 14(1): 44 50).

15 In the experiment described below we show the effect of Compound (1) on the angiogenesis induced by newly formed tumours following human tumour cell inoculation in animal models. Method 5 Tumour cells were inoculated intra-dermally in nude mice, Compound (I) 25 or 50 mg/kg or vehicle was given once daily p.o. with the first dose given on the day after cell implantation and the mice were sacrificed 5 days later. A 1 cm 2 area with the tumour at the centre was examined and the number of blood vessels bifurcations within that area supplying the tumour were counted. The number of vessels supplying tumours from animals treated with 10 test drug and vehicle were compared and the effect of Compound (I) was calculated as a percentage reduction of vessel count. Results Compound (I) caused reductions in blood vessel density around tumours in treated animals compared to vehicle controls. Reductions in vessel counts by Compound (1) were 15 seen around tumours induced by both colon and prostate cell lines in five in vivo studies. Table 2 Inhibition of angiogenesis in primary tumours caused by Compound (I) Cell Line Tumour Type Compound (1) dose (mg/kg) Inhibition of vessel count LOVO Colon 50 20% (P=0.001) LOVO Colon 50 28% (P<0.001) LOVO Colon 25 28% (P<0.001) DU145 Prostate so 30% (P<0.05) DU145 Prostate 25 38% (P<0.001) Table 2 statistically analyzed by the ANOVA test compared to vehicle controls The above cells lines are commercially available. One source is the ATCC (American 20 Type Culture Collection). LOVO has ATCC No =CCL-229. DU145 has ATCC No = HTB 81. Discussion We have shown that, in vitro, Compound (I) is an effective inhibitor of ET- I mediated activation of MAP kinase in osteoblasts as well as being effective in inhibiting angiogenesis 25 in primary tumours in vivo. This confirms the potential for this agent as a therapy in metastatic prostate cancer as it may have beneficial effects in preventing pathological bone density increases (by inhibition of osteoblastic proliferation), mediated by MAPK pathway as 16 well as inhibiting the release of growth factors which support the survival and growth of tumour cells in the bone microenvironment in addition to anti-angiogenesis effect at the pnmary tumour. 4) Compound (1) as an endothelin receptor antagonist in the human endothelin system 5 Human forearm blood flow can be assessed by temporarily impeding the venous drainage from the arm by the application of a pneumatic cuff on the upper arn, which is then inflated to just above venous pressure. The resulting arterial flow into the arm with no corresponding venous drainage leads to engorgement and swelling of the forearm, which can be detected with sensitive strain gauges. Infusion of the arterial vasoconstrictor ET-1 into the 10 brachial artery leads to a reduction in forearm distension due to decreased arterial inflow. This vasoconstriction is mediated via endothelin receptors on the vascular endothelium and associated smooth muscle. Method A study was performed to investigate the ability of Compound (1) to antagonise the 15 vasoconstrictor effect of ET-1 via endothelin receptors in this model in healthy male subjects aged 18-65. Eight subjects received single oral doses of 10 mg Compound (1), 30mg Compound (I) and placebo in a randomised, double blind manner on study days at least 7 days apart. Forearm vasoconstriction in response to ETI was assessed between 2 and 4 hours post dosing with Compound (I). 20 Results Overall, Compound (1) produced a statistically significant reduction in forearm blood flow in response to infused ET-1 compared to placebo (p=0.0210) with evidence of a dose response between the doses investigated. This demonstrates that Compound (I) is an endothelin receptor antagonist in the human endothelin system. 25 5) Compound (1) in a Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of Compound (I) given Orally Once Daily in Patient With Metastatic Prostate Cancer The following study can be undertaken to determine the maximum well tolerated dose (MVT7D) of Compound (1) in subjects with metastatic prostate cancer. This study will allow 30 you to observe the effect of Compound (1) on prostate-specific antigen (PSA), observe the effect of Compound (1) on a serological biomarker of bone metastasis and provide you with pharmacokinetic characterization of Compound (I) in subjects with metastatic prostate cancer.

17 Method Patients with prostate cancer who have documented bone metastases (confumed by bone scan within 3 months of study entry) can be used for this study. Compound (I) can be given orally once daily in tablet form. 120 mg can be used as the starting dose. Subjects can 5 be given study medication for 28 days or until withdrawal criteria are met. Each dose level can recruit up to three subjects with metastatic prostate cancer. A formal assessment of tolerability can be made in each subject following one week of Compound (I) administration. Dose escalation can occur when two subjects in any cohort have not experienced a dose limiting toxicity (DL T) following one week of continuous 10 Compound (I) administration. The dose can escalate by a factor of two at each step. If one subject at a particular dose level has a DLT, then two additional subjects at the same dose level must not experience DLTs in order to escalate to the next dose level. Subjects can continue therapy for twenty eight days unless the withdrawal criteria are met. When a minimum of two subjects in any cohort have been given a dose that is 15 considered to be not well tolerated at any time point after administration, dose escalation will end, and the closest dose below this will be taken as the MWTD. The following outcomes can be observed: > Incidence and severity of adverse events; > PSA concentration (total and ratio of free to total) at 1, 2, and 4 weeks in subjects 20 treated with Compound (1); > Change in PSA (total and ratio of free to total) from before Compound (I) administration to 1, 2 and 4 weeks after Compound (I) administration; > Change in a serum marker of bony metastatic involvement (bone alkaline phosphatase) from the level before Compound (I) administration to levels after 1, 2, 25 and 4 weeks of Compound (I) administration; and > Plasma concentrations and variables of Compound (I) following a single dose and multiple doses at steady state. Testing for pain relief The analgesic effect of Compound (I) may be measured, for example, in the murine 30 model of cancer pain described by Wacnik et al., Journal of Neuroscience (2001), 21, 9355. In a further embodiment of the present invention Compound (I), or a pharmaceutically acceptable salt thereof, is administered to a cell or individual prior to the development of cancer. For example, a person at risk of developing cancer may be treated with Compound (I), 18 or a pharmaceutically acceptable salt thereof, to prevent or inhibit the development of cancer and/or to prevent the development of metastases. Compound (I), or a pharmaceutically acceptable salt thereof, can be administered for therapeutic or prophylactic use to a warm blooded animal such as man by methods known in 5 the art. Administration can occur directly at the tumour site, or particularly, systemic administration. Compound (I), or a pharmaceutically acceptable salt thereof, can be administered for therapeutic or prophylactic use to a warm blooded animal such as man in the form of conventional pharmaceutical compositions. The composition may be in a form suitable for 10 oral administration, for example as a tablet or capsule, for parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion) as a sterile solution, suspension or emulsion, for topical administration as an ointment or cream or for rectal administration as a suppository. In general the above compositions may be prepared in a conventional manner using conventional excipients. For example, Compound (1) can be 15 formulated as a tablet using the following excipients: Compound (I); Lactose monohydrate (filler); Croscarmellose sodium (disintegrant); Povidone (binder); 20 Magnesium stearate (lubricant); Hypromellose (film coat component); Polyethylene glycol 300 (film coat component); and Titanium dioxide (film coat component). The amount of Compound (I), or a pharmaceutically acceptable salt thereof, 25 administered would be that sufficient to provide the desired pharmaceutical effect. For instance, Compound (I) could be administered to a warm-blooded animal orally, at a unit dose less than Ig daily. Particularly Compound (1) could be administered to a warm-blooded animal, at a unit dose of less than 250 mg per day. In another aspect of the invention, Compound (I) could be administered to a warm-blooded animal, at a unit dose of less than 30 130 mg per day. In a further aspect of the invention, Compound (I) could be administered to a warm-blooded animal, at a unit dose of less than 50 mg per day.

P 'OPER\DAF 5u25511 I d,, spcc doc./I-,/l.ll - 18A Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or 5 steps. The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that that prior publication (or information derived from it) or known matter forms part of the common general 10 knowledge in the field of endeavour to which this specification relates.

Claims (10)

1. The use of N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2 yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, in 5 the manufacture of a medicament for use in the prevention or treatment of pain in a warm blooded animal.

2. The use of N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2 yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, in 10 the manufacture of a medicament for use in the prevention or treatment of pain associated with elevated endothelin-1 production in a warm blooded animal.

3. The use of N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2 yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, in 15 the manufacture of a medicament for use in the prevention or treatment of pain associated with stimulation of the ETA receptor in a warm blooded animal.

4. The use according to any one of claims I to 3, wherein the warm blooded animal is man. 20

5. A method of treating or preventing pain comprising administering to a warm blooded animal in need thereof N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4 oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof. 25

6. A method of treating or preventing pain associated with elevated endothelin- 1 production comprising administering to a warm blooded animal in need thereof N-(3 methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3 sulphonamide, or a pharmaceutically acceptable salt thereof. 30 P'OPER\DAH\SpcU\208U\3025503 amededciams pages doc-23/04/2008 20

7. A method of treating or preventing pain associated with stimulation of the ETA receptor comprising administering to a warm blooded animal in need thereof N (3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3 5 sulphonamide, or a pharmaceutically acceptable salt thereof.

8. The method according to any one of claims 5 to 7 wherein the warm blooded animal is man. 10

9. The use according to any one of claims 1 to 3, substantially as hereinbefore described with reference to any one of the examples.

10. The method according to any one of claims 5 to 7, substantially as hereinbefore described with reference to any one of the examples. 15 20 25